Tech Transfer eNews Blog

Ben-Gurion U licenses out novel nasal spray delivery system for psychedelic drug therapies


By David Schwartz
Published: May 11th, 2022

BGN Technologies, the tech transfer arm of Ben-Gurion University of the Negev, has licensed a novel nasal spray for precise delivery of psychedelic drug therapies to Israeli biopharma company Madrigal Mental Care. The initial indication is in treating and preventing post-traumatic stress disorder (PTSD).

The nanotechnology-based delivery system made its debut this week at the Biomed Israel 2022 Life Science and HealthTech conference in Tel Aviv.

Approximately 3.5% of American adults had PTSD in the past year, with standard treatments

Involving psychotherapy along with medications that affect the neurotransmitters serotonin or norepinephrine (SSRIs and SNRIs). The remission rate, however, is high.

The experimental spray contains biodegradable nanoparticles encapsulating molecules of psychedelic substances such as psilocybin, ketamine, mescaline, and MDMA (Ecstasy).

“An increasing number of studies point to the advantages of using psychedelic drugs for the treatment of psychiatric disorders such as PTSD, depression, anxiety, obsessive compulsive disorder, and even addiction, with low doses,” said the system’s inventor, BGU Professor of Biomedical Engineering Amnon Sintov.  “Due to their powerful effect on the human brain, it is imperative to be able to deliver these drugs in a safe manner and in precise doses,” he said.

David Gabay, cofounder and chairman of Madrigal, said the system provides “a significant advantage over common practices in terms of stability and accuracy.”

“There is a vast need for better treatments for PTSD and other mental disorders,” noted Galit Mazooz Perlmuter of BGN Technologies. “We have filed a patent application to protect this unique approach.”

Source: Israel 21c

Posted under: Tech Transfer e-News